Quantcast

Latest Oncology Stories

2014-10-10 23:02:27

Susan G. Komen® Central and Northern Arizona (Komen CAN AZ) AZ calls on Arizona residents to support and register for 2014 Komen Phoenix Race for the Cure® on Sunday, October 12, 2014. In order to sustain local initiatives and 18 percent short from its targeted race participation goal, Komen CAN AZ aims to raise $415,000 more to meet its $1.2 million fundraising goal. PHOENIX, AZ (PRWEB) October 10, 2014 Susan G. Komen® Central and Northern Arizona (Komen CAN AZ) needs the...

2014-10-10 23:01:25

The Firm is evaluating potential legal claims on behalf of women who allegedly experienced the spread of uterine sarcoma and other gynecological cancers due to a power morcellator. New York, New York (PRWEB) October 10, 2014 A petition to ban the use of power morcellators (http://www.drugbot.com/morcellator/) in laparoscopic hysterectomies and other gynecological surgeries has gathered more than 85,000 signatures, Bernstein Liebhard LLP reports. According to figures posted on Change.org,...

2014-10-10 16:24:19

Women encouraged to receive life-saving screenings at mobile mammography unit on campus BOISE, Idaho, Oct. 10, 2014 /PRNewswire-USNewswire/ -- Early detection of breast cancer is key to a better prognosis, but only 25 to 35 percent of women in the southwest Idaho region who need mammograms are getting this life-saving medical screening. Broadview University-Boise is helping raise this number by partnering with Saint Alphonsus' Mobile Heath Screening Coach. The 40-foot long mobile...

2014-10-10 08:24:07

SAN DIEGO, Oct. 10, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. ("MabVax"), a clinical stage oncology drug development company, announced today that FINRA has approved a change in the Company's stock symbol. Effective today, the Company's common shares will commence trading on the OTC Bulletin Board under the trading symbol "MBVX" (OTCQB: MBVX.) The previous trading symbol was "TELK" (OTCQB: TELK). J. David Hansen, President and CEO of the Company, said, "We are...

2014-10-09 23:08:22

The first phase II trial of an experimental mesothelioma drug contains good news for patients with unresectable mesothelioma. Raleigh, NC (PRWEB) October 09, 2014 Scientists say the monoclonal antibody amatuximab may improve outcomes for mesothelioma patients on standard chemotherapy. Click here to read Surviving Mesothelioma’s newly-posted article on the new study. Researchers with the National Cancer Institute administered amatuximab along with cisplatin and pemetrexed to 89 pleural...

2014-10-09 16:27:54

Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE(®)) antibody construct, blinatumomab. The BLA is for the...

2014-10-09 16:24:03

Funds raised through the world's largest cancer cycling event series will power life-saving immunotherapy research, treatment and care in New York and around the world NEW YORK, Oct. 9, 2014 /PRNewswire/ -- New York's first annual Ride to Conquer Cancer launched to the public on Wednesday to raise vital funds for the Cancer Research Institute in Manhattan. Funds raised through the world's largest cancer cycling event series will power life-saving immunotherapy research in New York...

2014-10-09 12:29:10

- $5.8 million award will help advance the development of oxygen-carrying therapeutics for cancer - SAN CARLOS, Calif., Oct. 9, 2014 /PRNewswire/ -- Omniox, Inc., an IND-stage biopharmaceutical company developing therapeutics for hypoxic diseases, announced today that the company has been granted a Translation Fund Award from the Wellcome Trust. The $5.8 million award will advance development of Omniox's lead product, OMX-4.80, for the treatment of hypoxic cancers including...

2014-10-09 12:27:45

Proceeds Support Breast Cancer Research and Education CHICAGO, Oct. 9, 2014 /PRNewswire/ -- The Illinois Lottery today introduced the 11(th) edition of its breast cancer awareness instant lottery game, Carolyn Adams Ticket for the Cure, at the headquarters of Metropolitan Chicago Breast Cancer Task Force, a recent grant recipient of Ticket for the Cure funding. This was the first lottery game of its kind in the nation, and remains the only lottery game in the U.S. benefitting breast...

2014-10-09 08:27:59

DelMar Pharmaceuticals Presents Data at AACR's New Horizons in Cancer Research Conference in Shanghai, China VANCOUVER, British Columbia, MENLO PARK, Calif. and SHANGHAI, Oct. 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research:...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.